The GLP-1 scientists, Akiko Iwasaki, Michael J. Fox, Hadiza Galadanci, Vivek Murthy +92 more
Jens Juul Holst, Joel Habener, Svetlana Mojsov, and Dan Drucker PAVING THE WAY FOR WEIGHT-LOSS DRUGS
If [GLP-1 drugs] show benefit for even half of these conditions, then that will be a tremendous win for people struggling with them.' -DAN DRUCKER
Newly powerful weight-loss drugs became the biggest story in health in the past year-and Jens Juul Holst, Joel Habener, Svetlana Mojsov, and Dan Drucker played pivotal roles in making those medications possible. The scientists conducted the early work, beginning in the 1970s, on glucagon-like peptides, or GLPs, that first transformed the treatment of diabetes and now that of obesity.
As with many groundbreaking medical developments, it was a group effort. Holst, at the University of Copenhagen, noticed that after intestinal surgery, patients' levels of insulin soared while their blood-sugar levels dropped; he attributed the changes to several gut-related hormones, including glucagon, which is made in the pancreas. Around the same time, an ocean and a continent away in Boston, Habener and Drucker worked with animals in the lab at Massachusetts General Hospital and identified new types of glucagon hormones that they called GLP-1 and GLP-2. Mojsov, a chemist two floors away, also independently identified the active portion of GLP-1, which is mimicked in the new weight-loss drugs as the key compound in Ozempic and Wegovy (made by Novo Nordisk) and one of two main compounds in Mounjaro and Zepbound (made by Eli Lilly). Mojsov produced large amounts of the peptide and developed antibodies to stick to them. The trio eventually collaborated on critical scientific papers that described the active part of GLP-1 in the guts of rats, and documented that increasing GLP-1 levels corresponded to increasing levels of insulin.
Denne historien er fra May 13, 2024-utgaven av Time.
Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.
Allerede abonnent ? Logg på
Denne historien er fra May 13, 2024-utgaven av Time.
Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.
Allerede abonnent? Logg på
CAVALCADE OF COMEDY
As Saturday Night Live celebrates its 50th season, alumni look back on the people, moments, and humor that shaped their time at an American institution
The Summer of Scam that never ended
EARLY IN THE NEW NETFLIX SERIES APPLE CIDER VINEgar, its star, Kaitlyn Dever, breaks the fourth wall.
The Italian 'Trump whisperer'
ITALIAN PRIME MINister Giorgia Meloni's political fortunes are far brighter than any other G-7 leader's.
The (real) problem with fake plants
WHEN THE GERMAN PHILOSOPHER IMMANUEL KANT puzzled over why nature looks beautiful to us, he considered the case of replicas.
Insecurity is the new inequality
DONALD TRUMP'S SECOND PRESIDENTIAL TERM HAS already been accompanied by a cascade of unnerving political and natural events-from the U.S.'s leaving the World Health Organization and the Paris Climate Accords, to the nighttime firings of inspectors general and pardons of the Jan. 6 rioters, to the raids targeting immigrants in a number of cities and the wildfires roaring through swaths of Los Angeles.
TIME the Closers
25 BLACK LEADERS WORKING TO END RACIAL INEQUALITY
THE PAW PATROL PRINCIPLE
How a toy company built a children's-television juggernaut
Mindy Kaling The writer, producer, and showrunner on the status of Legally Blonde 3, cooking with Meghan Markle, and her new Netflix comedy, Running Point
The family in Running Point has shades of Succession. Was that show on your mind?
A THOUSAND CUTS
THE STANDOFF AT 1300 PENNSYLVANIA AVENUE was not much of a spectacle.
DeepSeek's hidden warning for AI safety
THE RELEASE OF DEEPSEEK R1 STUNNED WALL STREET and Silicon Valley in January, spooking investors and impressing tech leaders.
